Seropositivity – Page 10 – Communicable Diseases Research

Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test

현장 감시 검사로서 중화 항체 검출을 위한 SARS-CoV-2 신속 검사 키트의 진단 가치

Article

Published on 2022-04-272022-09-11
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

상트페테르부르크 인구에서 SARS-CoV-2 항체 혈청유병성에 대한 종단 무작위 코호트 연구

Randomized Controlled Trial

Published on 2022-04-272022-09-11
Journal: Viruses [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, 치료법,

[키워드] 95% CI Adults age anti-RBD antibodies antibody Antigen antigen receptor antigen receptor binding domain approved calculated calculator carried characteristic children Cohort conducted confidence Confidence intervals coronavirus coronavirus SARS-CoV-2 COVID-19 COVID-19 pandemic COVID-19 patient decrease died effort enzyme enzyme immunoassays FIVE form herd immunity Immunity immunoassays implementation increase in indicated interval less longitudinal material methodology nucleocapsid nucleocapsid antigen Older organized pandemic participated Participation Pasteur Institute percentage percentages Population proportion Quantitative Randomized RBD Receptor binding Receptor binding domain required Russia SARS-CoV-2 SARS-CoV-2 nucleocapsid seropositive Seropositivity Seroprevalence Seven significantly St. Petersburg Stage stages statistical significance statistically statistically significant vaccination Vaccine Vaccines Volunteer volunteers were assessed were recorded z-test
[DOI] 10.3390/v14050913 PMC 바로가기 [Article Type] Randomized Controlled Trial

Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients

중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2)가 장기간 지속되면 회복된 COVID-19 환자에서 단백질 특이성 및 중화 항체가 급증합니다.

Article

Published on 2022-04-212022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-RBD anti-receptor-binding domain Anti-spike Antibody Response Antibody responses Antibody titers Asymptomatic individuals blood sample Blood samples Cohort cohort of patient collected confirmed case coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 disease enrolled half-life IgA IgG IgG antibody IgG antibody titer Immunoglobulin immunological individual Infection Mild Mild disease Neutralizing neutralizing antibody Neutralizing titer neutralizing titers participant persistence Protein RBD recovered COVID-19 patient Recovered COVID-19 patients remained respiratory RT-PCR SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein Seropositivity serum antibody severe disease significantly Support symptom onset symptom severity total Ig understanding Vaccine wild-type SARS-CoV-2
[DOI] 10.1371/journal.pone.0267102 PMC 바로가기 [Article Type] Article

COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain

1차와 2차 전염병 사이(2020) 종합 암 센터 직원 사이의 COVID-19: 스페인 카탈로니아의 혈청 유병률 연구

Article

Published on 2022-04-212022-09-11
Journal: BMJ Open [Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] 95% CI 95% CIs adjusted age and sex antibody association blood sample Cancer cancer centre Care Complete Contact contact with COVID-19 COVID-19 infection COVID-19 patients cross-sectional study epidemic wave epidemiological survey Epidemiology Factor female First wave HCW HCWs Health Health care health care workers Health Education healthcare worker Healthcare workers higher risk hospitals household Infection median age medical staff no difference no differences no significant differences Nursing outcome pandemic Patient prevalence ratio Prevent preventive measure preventive measures reported risk factor SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 seroprevalence Serological testing seropositive participant seropositive participants Seropositivity Seroprevalence Severe COVID-19 Infection significant difference Sociodemographic characteristics Spain Spanish Surveillance the SARS-CoV-2 Transmission with COVID-19
[DOI] 10.1136/bmjopen-2021-056637 PMC 바로가기 [Article Type] Article

Underascertainment of COVID-19 cases among first responders: a seroepidemiological study

최초 대응자 중 COVID-19 사례의 과소 확인: 혈청 역학 연구

Article

Published on 2022-04-192022-09-11
Journal: Occupational medicine (Oxford, England) [Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted anti-SARS-CoV-2 antibody asked Care Cohort conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 case COVID-19 infection Descriptive statistics detect determine Elecsys elevated Emergency Care estimate examination firefighters first responders General population Germany high risk highlight immunoassay Infection infection risk information Logistic regression analysis measure mitigate occupational medicine paramedics participant past patients performed positive potential transmission Providing respiratory Responder risk factor Risk factors Roche Diagnostics SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection Sensitivity and specificity serological survey Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus Sociodemographic characteristics Support tested vaccination Workplace
[DOI] 10.1093/occmed/kqab164 PMC 바로가기 [Article Type] Article

Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary

Article

Published on 2022-04-112023-07-07
Journal: International journal of occupational medicine and environmental health [Category] COVID19(2023년),

[키워드] COVID-19 Healthcare workers medical students polymerase chain reaction SARS-CoV-2 Seropositivity
[DOI] 10.13075/ijomeh.1896.01804

An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status

중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염 및 B.1.1.7 항체 및 백신 접종 상태에 따른 의료 종사자의 변이 감염 발생률에 대한 관찰 코호트 연구

Observational Study

Published on 2022-04-092022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age anti-spike antibodies anti-spike antibody antibody B.1.1.7 B.1.1.7 variant BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Chain Reaction changes in confidence interval coronavirus coronavirus 2 detectable dose doses evade Evidence evidence of HCW HCWs healthcare healthcare worker Healthcare workers Immunity incidence incidence rate Infection investigated longitudinal cohort study natural natural immunity natural infection no evidence of Oxford-AstraZeneca pandemic PCR-positive Pfizer-BioNTech Poisson regression polymerase chain polymerase chain reaction provided rate ratio reduced respiratory resulting robust S-gene SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants Sequencing seronegative seropositive Seropositivity severe acute respiratory syndrome Coronavirus Sex Single-dose status symptomatic symptomatic and asymptomatic symptomatic infection United Kingdom vaccination Vaccine vaccine dose Vaccine-induced immunity whole genome Whole genome sequencing without symptom worker
[DOI] 10.1093/cid/ciab608 PMC 바로가기 [Article Type] Observational Study

Severe Acute Respiratory Syndrome Coronavirus 2 Cumulative Incidence, United States, August 2020-December 2020

중증 급성 호흡기 증후군 코로나바이러스 2 누적 발생률, 미국, 2020년 8월-2020년 12월

Article

Published on 2022-04-092022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법,

[키워드] accounted acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted Adults antibody antibody waning Antigen antigen capture assay black Blood calculated can not conducted coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic credible interval CrI cumulative cumulative incidence difference differential diagnosis disparity Emergency use fatality fraction IFR IgG IgM Immunoglobulin incidence infected with SARS-CoV-2 Infection infections nasal swab nasal swabs National nucleocapsid Probability probability survey provided public health random Random sample reported Reporting respiratory responses SARS-CoV-2 serology seropositive Seropositivity Severe acute respiratory syndrome specimen subgroup subgroups United States Viral Viral detection white
[DOI] 10.1093/cid/ciab626 PMC 바로가기 [Article Type] Article

Previous SARS-CoV-2 Infection Status Among the Current RT-PCR-Positive Individuals Affected During the Second Wave of COVID-19 Infections in Chennai, India

인도 첸나이에서 COVID-19 감염의 두 번째 물결 동안 영향을 받은 현재 RT-PCR-양성 개인 중 이전 SARS-CoV-2 감염 상태

Article

Published on 2022-04-042022-09-11
Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, 진단,

Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?

경증 및 무증상 SARS-CoV-2 감염을 감지하기 위한 핵단백질에 대한 혈청양성: COVID-19 백신 접종 후 획기적인 감염을 감지하기 위한 보완 도구?

Article

Published on 2022-04-012022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제,

[키워드] 95% confidence interval Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Asymptomatic asymptomatic individual Asymptomatic individuals Blood Breakthrough infection breakthrough infections complementary Concentration coronavirus country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines described detect determine explained first dose help IgG IgG response IgG responses immune response immunoassay Immunoglobulin Immunoglobulin G individual induce Infection median Mild multiplex immunoassay not affected nucleoprotein participant Participants Pfizer/BioNTech positive produced Protein qPCR respiratory response RT-qPCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections second dose sensitivity Seropositivity Serosurveillance severe acute respiratory syndrome Coronavirus spike Spike protein symptom onset target the Spike vaccinated individual vaccination virus were used
[DOI] 10.1016/j.vaccine.2022.03.009 PMC 바로가기 [Article Type] Article